A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Public ClinicalTrials.gov record NCT03219333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spread to nearby tissues or to other areas of the body. This clinical trial will enroll patients who were previously treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI). Some CPIs have been approved for the treatment of urothelial cancer. This study will test if the cancer shrinks with treatment. This study will also look at the side effects of the drug. A side effect is a response to a drug that is not part of the treatment effect. Patients who sign up for this trial must also fall into one of these categories: * Patients have already received treatment with platinum-containing chemotherapy * Patients have never received platinum-containing treatment and are not eligible for treatment with cisplatin.
Study identification
- NCT ID
- NCT03219333
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 219 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 8, 2017 (Actual)
- Primary completion
- Oct 27, 2020 (Actual)
- Completion
- Jul 28, 2023 (Actual)
- Last update posted
- Aug 27, 2024
2017 – 2023
United States locations
- U.S. sites
- 54
- U.S. states
- 24
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Urological Institute | Anchorage | Alaska | 99503 | — |
| Arizona Oncology Associates, PC - HAL | Goodyear | Arizona | 85395 | — |
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85710 | — |
| Keck Medical Center / University of Southern California | Los Angeles | California | 90033 | — |
| Keck Medical Center / Newport Beach | Newport Beach | California | 92663 | — |
| Kaiser Permanente Oakland | Oakland | California | 94611 | — |
| Chao Family Comprehensive Cancer Center University of California Irvine | Orange | California | 92868 | — |
| University of California Irvine - Newport | Orange | California | 92868 | — |
| Kaiser Permanente Roseville | Roseville | California | 95661 | — |
| University of California Davis | Sacramento | California | 95817 | — |
| Kaiser Permanente Sacramento | Sacramento | California | 95825 | — |
| Kaiser Permanente San Francisco | San Francisco | California | 94115 | — |
| Kaiser Permanente San Jose | San Jose | California | 95119 | — |
| Kaiser Permanente San Leandro | San Leandro | California | 94577 | — |
| Kaiser Permanente Santa Clara | Santa Clara | California | 95051 | — |
| Kaiser Permanente South San Francisco | South San Francisco | California | 94080 | — |
| Kaiser Permanente Medical Center Northern California | Vallejo | California | 94589 | — |
| Kaiser Permanente Walnut Creek | Walnut Creek | California | 94596 | — |
| Rocky Mountain Cancer Centers - Aurora | Aurora | Colorado | 80012 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Ocala Oncology Center | Ocala | Florida | 34474 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637-1470 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Johns Hopkins Medical Center | Baltimore | Maryland | 21231 | — |
| Maryland Oncology Hematology, P.A. | Rockville | Maryland | 20850 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute / Wayne State University | Detroit | Michigan | 48201 | — |
| Washington University in St Louis | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12208 | — |
| New York University (NYU) Cancer Institute | New York | New York | 10016 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| James P. Wilmot Cancer Center / University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| James Cancer Hospital / Ohio State University | Columbus | Ohio | 43210 | — |
| Northwest Cancer Specialists, P.C. | Tigard | Oregon | 97223 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Prisma Health | Greenville | South Carolina | 29615 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37204 | — |
| Texas Oncology - Austin Central | Austin | Texas | 78731 | — |
| Texas Oncology - Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Seattle Cancer Care Alliance / University of Washington | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03219333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2024 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03219333 live on ClinicalTrials.gov.